

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CLSA Premium Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6877)**

# **CHANGE OF DIRECTOR AND LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS**

## **CHANGE OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of CLSA Premium Limited (the “**Company**”) announces that:

- (a) Mr. Ma Xufei has tendered his resignation as the Company’s independent non-executive Director, the chairman of the Company’s remuneration committee and the member of each of the Company’s audit committee, corporate governance committee and nomination committee, due to other business engagements which require more of his dedication, with effect from 20 March 2024; and
- (b) Mr. Ma Anyang (“**Mr. Ma**”) has been appointed as the Company’s independent non-executive Director, the chairman of the Company’s remuneration committee and the member of each of the Company’s audit committee, corporate governance committee and nomination committee with effect from 21 March 2024.

Mr. Ma Xufei has confirmed that he has no claims against the Company and he has no disagreement with the Board and he is not aware of any matters that need to be brought to the attention of the Company’s shareholders or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation. The Board would like to express its sincere gratitude to Mr. Ma Xufei for his valuable contribution to the Company during his tenure of office.

Set out below is the biographical profile of Mr. Ma:

*Mr. Ma Anyang – Independent Non-Executive Director*

Mr. Ma, Justice of the Peace of New South Wales of Australia, aged 62, holds a Master's degree in herbal medicine and a Doctoral degree in medicine. He is an Australian registered Chinese herbal medicine practitioner and registered Chinese herbal dispenser. Additionally, Mr. Ma currently serves as the president of the Chinese Medicine Industry Council of Australia Ltd (CMIC). He is a standing member of the Australian mirror committee (HE031) of the Technical Committee 249 Traditional Chinese Medicine (ISO/TC 249) of the International Organization for Standardization. Furthermore, Mr. Ma is also a reference group member of the Chinese Medicine Board of Australia (CMBA) and an external advisory committee member of the traditional Chinese medicine program of Western Sydney University (WSU).

Save as disclosed above and as at the date of this announcement, Mr. Ma has not held any directorship in any other publicly listed companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (having the meaning ascribed to it under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on the Stock Exchange) of the Company.

As at the date of this announcement, Mr. Ma does not have, nor is deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) as recorded in the register required to be kept under section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers.

Mr. Ma confirmed that he met the independence criteria as set out in Rule 3.13 of the Listing Rules.

The term of Mr. Ma's service as an independent non-executive Director is subject to re-election at the forthcoming Company's annual general meeting and retirement by rotation in accordance with the provisions of the Company's articles of association. The director's fees of Mr. Ma under his appointment letter are HK\$240,000 per annum. The emoluments of Mr. Ma are determined by the Board based on the recommendation from the Company's remuneration committee with reference to the performance and profitability of the Company as well as his personal performance, remuneration benchmark in the industry and the prevailing market conditions and will be reviewed from time to time.

In respect of Mr. Ma's appointment, there is no other information which is discloseable pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter relating to his appointment, other than as stated above, that needs to be brought to the attention of the holders of securities of the Company.

The Board is delighted to extend a warm welcome to Mr. Ma on his appointment and is confident that the inclusion of Mr. Ma will make valuable contributions to the Group's healthcare business.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 25 April 2023 and shall remain suspended until further notice. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules.

## **LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS**

The Board of the Company are set out below:

### ***Executive Directors***

Mr. Yuan Feng (*Deputy Chief Executive Officer*)

Mr. Chung Cheuk Fan Marco

### ***Non-executive Directors***

Mr. Li Jiong (*Chairman*)

Mr. Xu Jianqiang

### ***Independent non-executive Directors***

Mr. Wu Jianfeng

Ms. Hu Zhaoxia

Mr. Ma Anyang

The Company has four Board committees, the membership of which is as follows:

<b>Committee</b>	<b>Audit Committee</b>	<b>Nomination Committee</b>	<b>Remuneration Committee</b>	<b>Corporate Governance Committee</b>
<b>Name of Directors</b>				
Mr. Li Jiong		Chairman		
Mr. Xu Jianqiang				Chairman
Mr. Yuan Feng			Member	
Mr. Wu Jianfeng	Member		Member	
Ms. Hu Zhaoxia	Chairman	Member		Member
Mr. Ma Anyang	Member	Member	Chairman	Member

By Order of the Board  
**CLSA Premium Limited**  
**Yuan Feng**  
*Executive Director*

Hong Kong, 20 March 2024

*As at the date of this announcement, the Directors are:*

***Executive Directors***

Mr. Yuan Feng (*Deputy Chief Executive Officer*)  
 Mr. Chung Cheuk Fan Marco

***Non-executive Directors***

Mr. Li Jiong (*Chairman*)  
 Mr. Xu Jianqiang

***Independent non-executive Directors***

Mr. Wu Jianfeng  
 Ms. Hu Zhaoxia  
 Mr. Ma Xufei